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OBJECTIVES This study was undertaken to determine whether enalapril had comparable efficacy in black
and white patients with asymptomatic left ventricular dysfunction (ALVD) in preventing the
development of symptomatic heart failure (HF).
BACKGROUND Recent studies have suggested that black patients with HF due to systolic dysfunction may
derive less benefit than white patients with HF when treated with the same medication.
METHODS This is a post hoc analysis of the 4,054 black and white participants of the Studies of Left
Ventricular Dysfunction Prevention Trial.
RESULTS Randomization to enalapril was associated with a comparable reduction in the relative risk of
the development of symptomatic HF in black (relative risk [RR] 0.67, 95% confidence
interval [CI] 0.49, 0.92, p  0.01) and white patients (RR 0.61, 95% CI 0.53, 0.70, p 
0.001). Treatment with enalapril was also associated with a comparable reduction in the risk
of the development of HF requiring medical therapy and the composite end point of death
or development of HF in black and white patients. Black as compared with white patients
with ALVD were at increased risk of the development of symptomatic HF (RR 1.81, 95% CI
1.51, 2.17, p  0.001) despite adjustment for available measures of disease severity.
CONCLUSIONS Despite the increased absolute risk in black patients compared with white patients for the
progression of ALVD, enalapril was equally efficacious in reducing the risk of progression of
ALVD in these two ethnic groups. (J Am Coll Cardiol 2002;40:311–7) © 2002 by the
American College of Cardiology Foundation
Although the possibility has been raised that black patients
derive less benefit than white patients from some medica-
tions used in the treatment of heart failure (HF) due to
systolic dysfunction (1,2), further studies are needed to test
this hypothesis, given its important public health implica-
tions. One recent report from the Studies of Left Ventric-
ular Dysfunction (SOLVD) databases demonstrated that
white but not black participants randomized to enalapril had
a significant reduction in the risk of hospitalization for HF
(1). We designed the present post hoc analysis to determine
whether enalapril delayed the progression of asymptomatic
left ventricular dysfunction (ALVD) to symptomatic HF in
both black and white subjects participating in the SOLVD
Prevention Trial. The SOLVD Prevention Trial had end
points designed to represent progression from ALVD to
symptomatic HF (3). These end points were unique to the
SOLVD Prevention Trial and had not been assessed in the
previous report (1), which had combined participants from
the SOLVD Treatment and Prevention trials. If there is a
differential response to enalapril therapy between these two
ethnic groups, we hypothesized that enalapril should also be
less efficacious in preventing the progression from ALVD to
symptomatic HF in black than in white subjects.
METHODS
Patient population. The SOLVD Prevention Trial was a
randomized, double-blind, placebo-controlled trial. A total
of 4,228 patients with ALVD were randomly assigned to
receive either enalapril or placebo at one of 83 hospitals
linked to 23 centers in the U.S., Canada, and Belgium.
Patients known to have heart disease who had an ejection
fraction 0.35 or less and who were not receiving diuretics,
digoxin, or vasodilators for the treatment of HF were
eligible for the SOLVD Prevention Trial. Patients were
allowed to receive diuretic therapy for hypertension, digoxin
for current or past atrial fibrillation, or nitrates for angina.
The rationale, design, and methods of the SOLVD Trials
have been described (3,4).
Defining the etiology of ALVD. For each enrolled par-
ticipant, the SOLVD site investigator determined the most
likely etiology of HF and indicated it on the baseline form.
Choices included: “ischemic,” “nonischemic,” and “other” as
determined by the individual SOLVD site investigators
after reviewing all available information. Subjects did not
routinely undergo cardiac catheterization or non-invasive
From the *Heart Failure Research Group, Cardiology Division, Department of
Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas;
and †Department of Preventive Medicine and Epidemiology, Loyola University,
Maywood, Illinois. Drs. Dries, Cooper and Drazner received support from the
Donald W. Reynolds Cardiovascular Clinical Research Center, Dallas, Texas. Dr.
Dries received support from the NIH (HL04455) and AHA, Texas affiliate
(0160002Y). Dr. Drazner was the recipient of a Doris Duke Clinical Scientist
Development Award from the Doris Duke Charitable Foundation, New York, New
York.
Manuscript received February 23, 2002; revised manuscript received April 3, 2002,
accepted April 17, 2002.
Journal of the American College of Cardiology Vol. 40, No. 2, 2002
© 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00
Published by Elsevier Science Inc. PII S0735-1097(02)01943-5
testing to make this determination. For the present analysis,
we refined the definition of ischemic etiology to minimize
misclassification. As done previously (5–7), the present
analysis defined a participant as having an ischemic etiology
of heart failure if any of the following was present: 1)
classification as ischemic etiology by original SOLVD
investigator; 2) history of prior myocardial infarction; or 3)
history of coronary artery bypass graft operation.
Definition of race. Self-identified racial/ethnic classifica-
tion was reported on the baseline SOLVD forms. The
choices that were available on the form included: black,
white, Hispanic, American Indian, Asian, and other.
Defining the development of HF. Information on clinical
status, the development of HF, use of medications other
than those prescribed as part of the study, adherence to the
study regimen, and side effects was systematically recorded
at each follow-up visit. For patients who died, were hospi-
talized, or developed HF, the cause of death, the primary
reason for hospitalization, and the development of HF were
ascertained and classified using standardized forms by each
center’s principal investigator, who was unaware of the
patient’s treatment assignment.
Four overlapping definitions of HF, of increasing sever-
ity, were used by the SOLVD Prevention Trial investiga-
tors: 1) development of HF, identified by the study physi-
cian on the basis of symptoms, signs, or need for changes in
therapy; 2) HF requiring the addition of a diuretic, digoxin,
or a vasodilator to the patients regimen (in the case of
patients already receiving these drugs at baseline, the addi-
tional drug had to be prescribed for this indication); 3)
hospitalization for HF; and 4) death due to progressive HF
(“pump-failure”). Patients classified as reaching the end
point of developing HF requiring therapy were also classi-
fied as developing HF. Other end points included the
composite of death or development of HF and the compos-
ite of death or HF hospitalization.
Statistical analyses. Of 4,228 subjects in the SOLVD
Prevention Trial, we excluded subjects if New York Heart
Association (NYHA) class was not I or II or if race was not
white or black, leaving a study population of 4,054. Dichot-
omous variables included race (black or white), gender,
etiology of left ventricular (LV) dysfunction (ischemic or
nonischemic), history of diabetes or hypertension, baseline
use of diuretics or beta-blockers, NYHA (I vs. II), serum
sodium (135 mEq/l or not). Continuous variables in-
cluded LV ejection fraction, age, heart rate, and serum
creatinine. Continuous variables were compared between
groups by the Student t test assuming unequal variance
where appropriate, and dichotomous variables were com-
pared with the Fisher exact test.
Univariate Cox proportional hazards models determined
the association of enalapril therapy with the time to devel-
opment of end points in black and in white patients.
Although patients were randomized to enalapril or placebo,
there were some baseline differences in black patients
randomized to enalapril and those randomized to placebo.
These baseline differences were adjusted for in multivariate
Cox proportional hazards models.
Analyses were conducted to examine the independent
association of race with the progression from ALVD to HF.
Bivariate screens identified 17 variables associated with
black race and with the development of HF (systolic blood
pressure (BP), heart rate, gender, etiology of LV dysfunc-
tion, serum creatinine, digoxin, hypertension, randomiza-
tion to enalapril, anti-arrhythmic use, age, hyponatremia,
etiology of LV dysfunction, diabetes mellitus, and diuretic
use). An automated stepwise selection process was used to
select nine of these potential confounders. Adding the
remaining eight potential confounders back to the model
(systolic BP, anti-arrhythmic use, beta-blocker use, atrial
fibrillation, diabetes, history of hypertension, digoxin use,
and diuretic use) did not change the relative risk associated
with black race; thus, these eight covariates were left out of
the final model. Kaplan-Meier curves, stratified by random-
ization to enalapril therapy, were constructed in black
participants and in white participants for three end points—
the development of HF, the development of HF requiring
therapy, and death or the development of HF. The log-rank
statistic was used to compare the event-free survival in
subjects randomized to enalapril or placebo in both blacks
and whites for each of these end points. Formal statistical
tests for evidence of interaction between randomization
assignment (enalapril or placebo) and race (black vs. white
participants) were conducted to test for evidence of heter-
ogeneity of treatment effect with regard to the association of
enalapril use and the risk for progression of ALVD in the
two groups. The interaction analysis was conducted using a
simple unadjusted model and a fully adjusted model using
the same covariates as in multivariate analysis. A p value
0.05 for the interaction term was considered significant
for evidence of heterogeneity of treatment effect for enala-
pril in the two groups. All statistical analyses were con-
ducted using Statistical Analysis Software (SAS), version
8.2 (SAS, Inc., Cary, North Carolina).
RESULTS
Baseline characteristics. The baseline characteristics of
black compared with white subjects are presented in Table
1, with each group further stratified according to random-
ization to placebo or enalapril. In white patients, there were
no significant differences in baseline characteristics between
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ALVD  asymptomatic left ventricular dysfunction
BP  blood pressure
HF  heart failure
LV  left ventricular
NYHA  New York Heart Association
SOLVD  Studies of Left Ventricular Dysfunction
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subjects randomized to enalapril or placebo. In black pa-
tients, those randomized to enalapril were more likely to be
women, have a history of hypertension, and had a higher
systolic BP. In comparing white subjects with black subjects,
white patients had a lower proportion of women and history
of diabetes mellitus or hypertension but had a higher
proportion with an ischemic etiology of systolic dysfunction
and baseline beta-blocker use.
Unadjusted incidence in each group according to ran-
domization assignment. The unadjusted incidence of end
points that represent progression of ALVD for black and
white participants stratified by randomization to enalapril or
placebo is shown in Table 2. The black participants dem-
onstrated an increased incidence of each end point defining
disease progression as compared with whites. There was a
significant reduction in incidence rates for each end point in
the patients randomized to enalapril therapy in both black
and white subjects. The unadjusted event curves (Fig. 1)
demonstrate large differences in the absolute risk between
the respective placebo groups in black and white subjects for
the development of HF, development of HF requiring
therapy, and the composite of death or development of HF.
However, the relative risk reduction associated with ran-
domization to enalapril for these end points was significant
and of similar magnitude in both the black and white
participants.
Univariate analyses (Table 2). Randomization to enalapril
was associated with a significant reduction in the risk for
development of symptoms of HF, symptoms requiring the
addition of a vasodilator or digoxin, and the combined end
point of death or development of HF in both black and
white subjects. Randomization to enalapril was associated
with a significant reduction in the risk of first hospitaliza-
tion for HF or the combined end point (death or first HF
hospitalization) in the white subjects but not in the black
subjects. However, the 95% confidence intervals of the
relative risk associated with randomization to enalapril
overlapped between the black and white subjects, and
formal tests for heterogeneity of treatment effect (interac-
tion) between the groups were not significant for these end
points (Table 3).
Multivariate analyses (Table 3). We performed multivar-
iate analyses to adjust for the differences in baseline char-
acteristics of black patients randomized to placebo or
enalapril. In addition, formal statistical testing for interac-
tion between randomization and race was conducted to test
for heterogeneity of treatment effect using unadjusted and
adjusted modeling. The adjusted analyses demonstrated
little difference compared with the treatment effects dem-
onstrated in unadjusted analyses. In addition, there was no
significant statistical evidence for heterogeneity of treatment
effect with enalapril for any of the end points.
Increased progression of ALVD in black subjects.
Multivariate analysis was performed to determine the inde-
pendent risk associated with black race for the progression
of ALVD (Table 4). In these analyses, black subjects
remained at increased risk compared with the white subjects
for the progression of ALVD to each of the end points
despite adjustment for other markers of disease severity.
Table 1. Baseline Characteristics in Black and White Participants in the SOLVD Prevention
Trial Stratified According to Randomization to Enalapril or Placebo









Age (yrs) 58 56 59 60
Ejection fraction (%) 27 28 29 28
NYHA (%)
Class I 72 68 66 67
Class II 28 32 34 33
Gender (%)
Male 75 82* 90 90
Female 25 18 10 10
Etiology (%)
Ischemic 66 64 90 88
Nonischemic 34 36 10 12
History of diabetes (yes) (%) 27 24 14 14
Hypertension (%) 66 54* 34 35
Beta-blockers (%) 18 14 25 25
Diuretics (%) 38 40 15 14
Digoxin (%) 10 9 12 14
Systolic blood pressure (mm Hg) 129 124* 124 125
Heart rate (beats/min) 77 79 74 75
Serum creatinine (mg/dl) 1.2 1.3 1.1 1.1
Serum sodium (mEq/l) 140 140 140 140
*p  0.05 for comparison between black patients treated with placebo or enalapril.
NYHA  New York Heart Association; SOLVD  Studies of Left Ventricular Dysfunction.
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DISCUSSION
Despite recent concerns that angiotensin-converting en-
zyme (ACE) inhibitors may be less efficacious in black
patients with HF (1), the present study demonstrates that
enalapril significantly reduced the risk of development of
HF in both blacks and whites with asymptomatic LV
systolic dysfunction. Enalapril resulted in a comparable
reduction in the risk of the development of symptoms of
HF, the need to start medications for symptoms of HF, and
the combined end point of death or the development of
symptoms of HF in both blacks and whites with ALVD.
These data demonstrate that there is no evidence for
heterogeneity of treatment effect in black and white patients
with regard to the ability of ACE inhibitors to reduce the
risk for progression from ALVD to symptomatic HF. The
consistency of results in black and white subjects strength-
ens the argument that ACE-inhibitor therapy should con-
tinue to be used in black patients with HF (8,9).
Comparison with previous studies. Previous retrospective
studies that have addressed whether ACE inhibitors are
efficacious in black patients with HF are inconclusive. Data
from the Vasodilator–Heart Failure Trial investigators can
be interpreted to show either that ACE inhibitors are not as
efficacious in blacks as in whites or that the combination of
isosorbide and hydralazine is particularly beneficial in black
patients (10,11). A recent report that combined the
SOLVD Prevention and Treatment Trials and used a
matched analysis of black and white subjects showed that
enalapril use was associated with a reduction in the risk for
HF hospitalization in white but not black subjects, and
there was statistical evidence for heterogeneity of treatment
effect in this analysis (1). In the present study, the effect of
enalapril in reducing the risk of either first hospitalization
for HF or the composite end point (death or first hospital-
ization for HF) was not nominally significant in the black
subjects but was significant in the white subjects, although
formal evidence of statistical interaction between treatment
effect and ethnicity was not present. In light of the previous
study by Exner et al. (1), we are unable to determine
whether these findings represent a lack of statistical power
to detect heterogeneity of treatment effects in these two
ethnic groups or whether they represent lack of statistical
power to detect efficacy of enalapril for these end points in
the small number of black participants. The latter hypoth-
esis is supported both by the fact that the point estimates of
relative risk associated with enalapril use in black subjects
for these end points were less than one, and of comparable
magnitude to those associated with enalapril use in the
Table 2. Unadjusted Incidence and Relative Risk for Progression Asymptomatic Left Ventricular Dysfunction in Black and White
Participants According to Randomization to Enalapril or Placebo
Black Participants








Development of symptoms of HF 95 (46) 25.1 70 (35.9) 16.6 0.69 (0.51–0.93)
0.02
Development of symptoms and addition of HF medications 67 (32.2) 15.5 43 (22) 9.1 0.61 (0.41–0.89)
0.01
Death or development of HF symptoms 117 (56.3) 30.9 93 (47.4) 22.1 0.74 (0.56–0.97)
0.03
First hospitalization for HF 43 (20.7) 8.9 37 (19) 7.6 0.85 (0.55–1.32)
0.46
Death or first hospitalization for HF 78 (37.5) 16.1 68 (34.9) 13.9 0.86 (0.62–1.19)
0.36
White Participants







Development of symptoms of HF 512 (28) 12.1 339 (18.6) 7.3 0.62 (0.54–0.71)
0.001
Development of symptoms and addition of HF medications 386 (21.1) 8.6 227 (12.5) 4.6 0.55 (0.47–0.65)
0.001
Death or development of HF symptoms 666 (36.4) 15.8 505 (27.7) 10.8 0.70 (0.63–0.79)
0.001
First hospitalization for HF 214 (11.7) 4.4 142 (7.8) 2.8 0.64 (0.52–0.79)
0.001
Death or first hospitalization for HF 419 (22.8) 8.6 354 (19.4) 7.0 0.81 (0.74–0.97)
0.004
*Events per 100 participant-years of follow-up. †Relative risk for patients randomized to enalapril relative to placebo.
CI  confidence interval; HF  heart failure; RR  relative risk.
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white subjects, and because enalapril was equally efficacious
in reducing the risk for the development of symptomatic
HF in both groups.
It has been demonstrated that black patients with symp-
tomatic HF are at increased risk for death and HF progres-
sion compared with whites despite adjustments for differ-
ences in HF severity, comorbidities, and socioeconomic
factors (5). The present analysis extends these findings by
demonstrating that the absolute risk for progression from
ALVD to symptomatic HF is substantially greater in blacks
than in whites (Fig. 1). Despite the comparable relative
reduction in risk associated with enalapril in the two groups,
the differences in the baseline magnitude of risk was such
that blacks randomized to enalapril remained at higher risk
Figure 1. The cumulative incidence of end points representing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure
(HF). The development of HF (A), development of HF requiring medical therapy (B), and the composite end point of death or development of HF (C)
are shown for black and for white participants stratified by treatment of assignment (placebo and enalapril). In both black and white participants,
randomization to enalapril resulted in a significant reduction in the risk of development of these end points (p  0.001 for the comparison of white
participants treated with enalapril versus placebo for each of these three end points; for the comparison of black participants treated with enalapril versus
placebo: p  0.02 for development of HF, p  0.01 for development of HF requiring therapy, and p  0.03 for the composite end point of death or
development of HF). All p values are from the log-rank test.
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than whites randomized to placebo for the development of
HF. These differences between black and white subjects in
the risk of progression of ALVD persisted after adjusting
for potential confounders including ejection fraction,
NYHA class, serum sodium, and etiology of LV dysfunc-
tion. We interpret these findings to suggest either that
residual confounding persists or that there are differences in
the natural history of ALVD in blacks compared with
whites. Clearly, statistical adjustment based upon a single,
unstandardized measurement of the variables collected in
SOLVD could result in residual confounding. On the other
hand, if the latter hypothesis is true, one potential explana-
tion may be ethnic differences in the etiology of LV systolic
dysfunction (11).
Study limitations. There are several important limitations
of this retrospective study. The absolute number of black
patients in the study was small. The composite end point of
death or development of HF was predominantly driven by
the development of HF, whereas the end point of develop-
ment of HF requiring therapy was a subset of the end point
of the development of HF. Thus, the efficacy of enalapril in
black subjects demonstrated in this study was predomi-
nantly based on this one end point (development of HF). In
comparing the risk for progression to symptomatic HF
between black and white subjects, we cannot exclude the
possibility of residual confounding by variables not adjusted
for in the multivariate models.
Clinical implications. The validity of race as a construct in
medical research has been questioned (12–14). However,
the possibility of differential responses to pharmacologic
therapy between ethnic groups has been suggested by recent
data showing that black patients with HF derive less benefit
than white patients from enalapril (1) and some (2) but not
all (15) beta-blockers. We believe the present study dem-
onstrates that ACE inhibitors are efficacious in black
patients with systolic dysfunction. These findings are con-
cordant with the recent African American Study of Kidney
Disease and Hypertension that demonstrated a benefit of
ACE-inhibitor therapy in black patients with renal disease
(16). Our study adds support to the recommendation (9)
that therapies demonstrated to improve survival in large
randomized trials continue to be prescribed to all patients
with HF irrespective of their ethnicity.
Potential racial variation in drug response will become an
increasingly important question in clinical medicine. Racial
categories combine social and biological effects in complex
ways, however, and there are no adequate methods for
eliminating this confounding (13,14). Genomic research
continues to demonstrate the limited variation across pop-
ulation groups: virtually all human genetic diversity, includ-
ing that found at the ACE gene, is represented in African-
origin populations (17–19), and they therefore should be
unlikely to display phenotypic responses that diverge sharply
from those found in all other populations. In a sample of
populations, Wilson et al. (20) recently compared standard
ethnic labels against a clustering algorithm based directly on
genetic markers to predict variation in enzymes that modify
Table 3. Multivariate Analyses: Risk Associated With Randomization to Enalapril Versus
Placebo for Progression of Asymptomatic Left Ventricular Dysfunction
Blacks (n  403)
RR (95% CI)
p Value









Development of symptoms of HF 0.67 (0.49–0.92) 0.61 (0.53–0.70)
p  0.013 p  0.001 0.50 0.66
Development of symptoms and addition
of HF medication
0.58 (0.39–0.86) 0.55 (0.47–0.65)
p  0.006 p  0.001 0.66 0.92
Death or development of symptoms of
HF
0.71 (0.54–0.95) 0.70 (0.62–0.78)
p  0.02 p  0.001 0.72 0.74
First hospitalization for HF 0.84 (0.53–1.31) 0.64 (0.52–0.80)
p  0.44 p  0.001 0.23 0.28
Death or first hospitalization for HF 0.83 (0.60–1.16) 0.82 (0.71–0.94)
p  0.29 p  0.005 0.71 0.82
Adjusted for the following variables: age, gender, ejection fraction, New York Heart Association class, etiology of asymptomatic
left ventricular dysfunction, history of hypertension, systolic blood pressure, and baseline use of beta-blocker. *Interaction term
introduced into Cox proportional hazards model. †Only randomization assignment, race and interaction term in model.
‡Identical covariates used in multivariate stratified analyses included in model with interaction term.
CI  confidence interval; HF  heart failure; RR  relative risk.
Table 4. Adjusted Risk for Progression to End Points in Black
Relative to White Participants in SOLVD Prevention Trial
End Point
Black vs. White
RR (95% CI) p Value
Development of symptoms of HF 1.81 (1.51–2.17) 0.001
Development of symptoms and addition of
HF medication
1.53 (1.23–1.92) 0.001
Death or development of symptoms of HF 1.72 (1.46–2.02) 0.001
First hospitalization for HF 1.71 (1.31–2.24) 0.001
Death or first hospitalization for HF 1.62 (1.33–1.96) 0.001
Adjusted for following covariates: age, ejection fraction, New York Heart Association
class, etiology of left ventricular systolic dysfunction (ischemic vs. nonischemic), heart
rate, serum creatinine, low serum sodium, diabetes mellitus, and randomization to
enalapril or placebo.
CI  confidence interval; HF  heart failure; RR  relative risk; SOLVD 
Studies of Left Ventricular Dysfunction.
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drug responses. Genetic markers of population origin im-
proved prediction over ethnic labels in 3 of 4 enzymes
studied, although neither system was very precise. These
data demonstrate that race can be a very weak proxy for drug
response (14).
Conclusions. Black patients with ALVD are at increased
risk as compared with white patients for the development of
HF. Enalapril appears to be equally efficacious in black and
white patients in reducing the risk of progression from
ALVD to symptomatic HF.
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